Multiple myeloma cells undergo differentiation upon exposure to rosiglitazone and all-trans retinoic acid

References

• Mangelsdorf D J, Thummel C, Beato M, Herrlich P, Schütz G, Umesono K, et al. The nuclear receptor superfamily: the second decade. Cell 1995; 83: 835–839
   PubMed Web of Science ®Google Scholar
• Chawla A, Schwarz E, Dimaculangan D, Lazar M A. Proliferator-activated receptor (PPAR) gamma: adipose predominant expression and induction early in adipocyte differentiation. Endocrinology 1994; 135: 798–800
   PubMed Web of Science ®Google Scholar
• Spiegelman B. PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. Diabetes 1998; 47: 507–514
   PubMed Web of Science ®Google Scholar
• Elstner E, Williamson E A, Zang C, Fritz J, Heber D, Fenner M, et al. Novel therapeutic approach: ligands for PPARγ and retinoid receptors induce apoptosis in bcl-2-positive human breast cancer cells. Breast Cancer Res Treat 2002; 74: 155–165
   PubMed Web of Science ®Google Scholar
• Chang T H, Szabo E. Induction of differentiation and apoptosis by ligands of peroxisome proliferater activated receptor gamma in non-small cell lung cancer. Cancer Res 2000; 60: 1129–1138
   PubMed Web of Science ®Google Scholar
• Sarraf P, Mueller E, Jones D, Evans R M, Martin K J, Zhang M, et al. Differentiation and reversal of malignant changes in colon cancer through PPARγ. Nat Med 1998; 4: 1046–1052
   PubMed Web of Science ®Google Scholar
• Hisatake J I, Ikezoe T, Carey M, Holden S, Tomoyasu S, Koeffler H P. Down-regulation of prostate-specific antigen expression by ligands for peroxisome proliferator-activated receptor gamma in human prostate cancer. Cancer Res 2000; 60: 5494–5498
   PubMed Web of Science ®Google Scholar
• Motomura W, Okumura T, Takahashi N, Obara T, Kohgo Y. Activation of peroxisome proliferator-activated receptor gamma by troglitazone inhibits cell growth through the increase of p27Kip1 in human pancreatic carcinoma cells. Cancer Res 2000; 60: 5558–5564
   PubMed Web of Science ®Google Scholar
• Laurora S, Pizzimenti S, Briatore F, Fraioli A, Maggio M, Reffo P, et al. Peroxisome proliferator-activated receptor ligands affect growth- related gene expression in human leukemic cells. J Pharmacol Exp Ther 2003; 305: 932–942
   PubMed Web of Science ®Google Scholar
• Padilla J, Leung E, Phipps R P. Human B lymphocytes and B lymphomas express PPAR-g and are killed by PPAR-gamma agonists. Clin Immunol 2002; 103: 22–33
   PubMed Web of Science ®Google Scholar
• Tontonoz P, Singer S, Forman B M, Sarraf P, Fletcher J A, Fletcher C D, et al. Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator activated receptor and the retinoid X receptor. Proc Natl Acad Sci USA 1997; 94: 237–241
   PubMed Web of Science ®Google Scholar
• Tontonoz P, Nagy L, Alvarez J G, Thomazy V A, Evans R M. PPAR promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell 1998; 93: 241–252
   PubMed Web of Science ®Google Scholar
• Kawa S, Nikaido T, Unno H, Usuda N, Nakayama K, Kiyosawa K. Growth inhibition and differentiation of pancreatic cancer cell lines by PPAR gamma ligand troglitazone. Pancreas 2002; 24: 1–7
   PubMed Web of Science ®Google Scholar
• Konopleva M, Elstner E, McQueen T J, Tsao T, Sudarikov A, Hu W, et al. Peroxisome proliferator-activated receptor; and retinoid X receptor ligands are potent inducers of differentiation and apoptosis in leukemias. Mol Cancer Ther 2004; 3: 1249–1262
   PubMed Web of Science ®Google Scholar
• Ray D M, Bernstein S H, Phipps R P. Human multiple myeloma cells express peroxisome proliferator-activated receptor gamma and undergo apoptosis upon exposure to PPARgamma ligands. Clin Immunol 2004; 113: 203–213
   PubMed Web of Science ®Google Scholar
• Eucker J, Bangeroth K, Zavrski I, Krebbel H, Zang C B, Heider U, et al. Ligands of peroxisome proliferator-activated receptor c induce apoptosis in multiple myeloma. Anticancer Drugs 2004; 15: 955–960
   PubMed Web of Science ®Google Scholar
• Nolte R T, Wisely G B, Westin S, Cobb J E, Lambert M H, Kurokawa R, et al. Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-γ. Nature 1998; 395: 137–143
   PubMed Web of Science ®Google Scholar
• Desvergne B, Wahli W. Peroxisome proliferator-activated receptors: nuclearcontrol of metabolism. Endocr Rev 1999; 20: 649–688
   PubMed Web of Science ®Google Scholar
• Deeks E D, Keam S J. Rosiglitazone: a review of its use in type 2 diabetes mellitus. Drugs 2007; 67: 2747–2779
   PubMed Web of Science ®Google Scholar
• Giguere V, Ong E S, Segui P, Evans R M. Identification of a receptor for the morphogen retinoic acid. Nature 1987; 330: 624–629
   PubMed Web of Science ®Google Scholar
• Mangelsdorf D J, Ong E S, Dyck J A, Evans R M. Nuclear receptor that identifies a novel retinoic acid response pathway. Nature 1990; 345: 224–229
   PubMed Web of Science ®Google Scholar
• Maniratanachote R, Minami K, Katoh M, Nakajima M, Yokoi T. Chaperone proteins involved in troglitazone induced toxicity in human hepatoma cell lines. Toxicol Sci 2005; 83: 293–302
   PubMed Web of Science ®Google Scholar
• Van Riet I, Van Camp B. The involvement of adhesion molecules in the biology of multiple myeloma. Leuk Lymphoma 1993; 9: 441–452
   PubMed Web of Science ®Google Scholar
• Kawano M M, Huang N, Harada H, Harada Y, Sakai A, Tanaka H, et al. Identification of immature and mature myeloma cells in the bone marrow of human myelomas. Blood 1993; 82: 564–570
   PubMed Web of Science ®Google Scholar
• Mehta J, Singhal S. Myeloma. Taylor and Francis, London 2002; 539
   Google Scholar
• Child J A, Morgan G J, Davies F E, Owen R G, Bell S E, Hawkins K, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348: 1875–1883
   PubMed Web of Science ®Google Scholar